Cynata Therapeutics Limited (CYYNF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cynata Therapeutics Limited (CYYNF) with AI Score 54/100 (Hold). Cynata Therapeutics Limited is an Australian biotechnology company focused on developing and commercializing its Cymerus mesenchymal stem cell technology for various therapeutic applications. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Cynata Therapeutics Limited (CYYNF) Healthcare & Pipeline Overview
Cynata Therapeutics Limited, an Australian biotech firm, leverages its proprietary Cymerus mesenchymal stem cell technology to develop therapies for graft-versus-host disease, osteoarthritis, and diabetic wounds. With a strategic partnership with Fujifilm, Cynata aims to provide clinical and commercial manufacturing for its cell-based products, positioning itself in the regenerative medicine sector.
Investment Thesis
Cynata Therapeutics presents a compelling investment thesis centered on its Cymerus mesenchymal stem cell technology. The Phase III trial for CYP-004 in osteoarthritis represents a near-term value driver, with positive results potentially leading to regulatory approval and commercialization. The company's strategic partnership with Fujifilm provides a robust manufacturing foundation. Cynata's diversified pipeline, targeting indications like GvHD and diabetic wounds, offers multiple avenues for growth. With a market capitalization of $0.05 billion and a high gross margin of 253.3%, Cynata demonstrates financial efficiency. However, investors should be aware of the risks associated with clinical trial outcomes and regulatory hurdles, which could impact the stock's performance. The company's negative P/E ratio of -9.03 indicates it is not currently profitable.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.05 billion indicates a small-cap biotechnology company.
- P/E ratio of -9.03 reflects current lack of profitability, common in early-stage biotech firms.
- Profit Margin of 9887.9% suggests potential for high profitability upon commercialization of successful products.
- Gross Margin of 253.3% highlights efficient cost management in product development.
- Beta of 1.04 indicates the stock's volatility is similar to the overall market.
Competitors & Peers
Strengths
- Proprietary Cymerus technology platform.
- Strategic partnership with Fujifilm.
- Diversified pipeline of product candidates.
- Strong intellectual property protection.
Weaknesses
- Limited financial resources.
- Dependence on clinical trial outcomes.
- Regulatory hurdles for stem cell therapies.
- Competition from larger biotechnology companies.
Catalysts
- Upcoming: Phase III clinical trial results for CYP-004 in osteoarthritis.
- Upcoming: Potential regulatory approvals for CYP-001 or CYP-004.
- Ongoing: Expansion of the Cymerus technology into new therapeutic areas.
- Ongoing: Strategic partnerships and collaborations.
- Ongoing: Publication of clinical data in peer-reviewed journals.
Risks
- Potential: Clinical trial failures.
- Potential: Regulatory setbacks.
- Potential: Competition from established therapies.
- Potential: Economic downturns.
- Ongoing: Limited financial resources.
Growth Opportunities
- Osteoarthritis Treatment (CYP-004): The global osteoarthritis market is substantial, projected to reach $13.4 billion by 2028. Cynata's CYP-004, currently in Phase III trials, targets this large market. Positive trial results and subsequent regulatory approval could drive significant revenue growth. The timeline for potential commercialization is estimated within the next 2-3 years, assuming successful trial outcomes and regulatory clearance. Cynata's competitive advantage lies in its allogeneic cell therapy approach, which could offer a more scalable and cost-effective solution compared to existing treatments.
- Graft-versus-Host Disease (CYP-001): Graft-versus-host disease (GvHD) represents a significant unmet medical need, particularly in patients undergoing hematopoietic stem cell transplantation. Cynata's CYP-001, having completed Phase I trials, targets this indication. The market for GvHD treatments is growing, driven by increasing transplantation procedures. Successful development and commercialization of CYP-001 could provide a valuable revenue stream for Cynata. The timeline for potential market entry is estimated within the next 3-5 years, contingent on further clinical development and regulatory approvals.
- Diabetic Wound Care (CYP-006TK): Diabetic wounds pose a significant challenge due to impaired healing capabilities. Cynata's CYP-006TK, a novel polymer-coated silicon wound dressing, aims to address this issue. The diabetic wound care market is expanding, fueled by the rising prevalence of diabetes. Successful development and commercialization of CYP-006TK could offer a valuable addition to Cynata's product portfolio. The timeline for potential market entry is estimated within the next 2-4 years, pending further development and regulatory clearances.
- Strategic Partnerships: Cynata's strategic partnership with Fujifilm provides a robust foundation for clinical and commercial manufacturing of its Cymerus-based products. This collaboration ensures scalability and reliability in production, which is crucial for meeting potential market demand. Leveraging Fujifilm's expertise and infrastructure can accelerate Cynata's growth trajectory and reduce manufacturing-related risks. The ongoing partnership strengthens Cynata's competitive position in the regenerative medicine space.
- Expansion into New Therapeutic Areas: Cynata is exploring the potential of its Cymerus technology in various other indications, including asthma, heart attack, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. This diversified approach offers multiple avenues for growth and reduces the company's reliance on a single product or indication. Successful expansion into these new therapeutic areas could significantly enhance Cynata's long-term growth prospects.
Opportunities
- Expanding into new therapeutic areas.
- Securing additional partnerships and collaborations.
- Obtaining regulatory approvals for its product candidates.
- Increasing awareness of its Cymerus technology.
Threats
- Clinical trial failures.
- Regulatory setbacks.
- Competition from established therapies.
- Economic downturns.
Competitive Advantages
- Proprietary Cymerus technology platform for MSC production.
- Strong patent portfolio protecting its MSC technology.
- Strategic partnership with Fujifilm for manufacturing and supply.
- Clinical data supporting the safety and efficacy of its product candidates.
About CYYNF
Cynata Therapeutics Limited, founded in 2003 and based in Cremorne, Australia, is a biotechnology company dedicated to developing and commercializing a proprietary mesenchymal stem cell (MSC) technology known as Cymerus. This technology aims to address critical unmet medical needs through regenerative medicine. The company's journey began as Eco Quest Limited before rebranding to Cynata Therapeutics in October 2013, marking a strategic shift towards therapeutic development. Cynata's lead product candidate, CYP-001, has completed Phase I clinical trials for treating graft-versus-host disease (GvHD), a severe complication following stem cell transplantation. The company is also advancing CYP-004, currently in Phase III clinical trials, for the treatment of osteoarthritis, a prevalent and debilitating joint condition. Additionally, Cynata is developing CYP-006TK, a novel polymer-coated silicon wound dressing designed for diabetic wounds, addressing the challenges of impaired healing in diabetic patients. Beyond these core programs, Cynata is exploring the potential of its Cymerus technology in various other indications, including asthma, heart attack, coronary artery disease, acute respiratory distress syndrome, brain cancer, sepsis, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation, showcasing the versatility of its platform. A key strategic partnership with Fujifilm supports the clinical and commercial manufacturing and supply of Cynata's Cymerus-based therapeutic products, ensuring scalability and reliability in production.
What They Do
- Develops mesenchymal stem cell (MSC) technology under the Cymerus brand.
- Focuses on therapeutic applications for human diseases.
- Conducts clinical trials for product candidates.
- Partners with Fujifilm for manufacturing and supply of Cymerus products.
- Targets graft-versus-host disease (GvHD) with CYP-001.
- Develops CYP-004 for the treatment of osteoarthritis.
- Creates CYP-006TK for diabetic wound care.
- Explores treatments for asthma, heart attack, and other diseases.
Business Model
- Develops and patents mesenchymal stem cell (MSC) technology.
- Out-licenses technology or partners with other companies for commercialization.
- Generates revenue through milestone payments and royalties from partnered products.
- Conducts internal research and development to expand the application of its Cymerus technology.
Industry Context
Cynata Therapeutics operates within the rapidly evolving biotechnology industry, specifically focusing on regenerative medicine and stem cell therapies. The market for stem cell therapies is projected to reach billions of dollars by 2030, driven by the increasing prevalence of chronic diseases and the demand for innovative treatments. The competitive landscape includes companies like CBSTF (Caladrius Biosciences), DSOL (Direxis Surgical), DTCFF (DermTech), MDDVF (Medexus Pharmaceuticals), and MMIRF (MIMEDX Group), each pursuing different approaches within the regenerative medicine space. Cynata's Cymerus technology offers a unique allogeneic approach, potentially providing scalability and cost-effectiveness advantages over autologous cell therapies.
Key Customers
- Patients suffering from graft-versus-host disease (GvHD).
- Patients with osteoarthritis.
- Patients with diabetic wounds.
- Pharmaceutical companies seeking to license or partner on stem cell therapies.
Financials
Chart & Info
Cynata Therapeutics Limited (CYYNF) stock price: Price data unavailable
Latest News
No recent news available for CYYNF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CYYNF.
Price Targets
Wall Street price target analysis for CYYNF.
MoonshotScore
What does this score mean?
The MoonshotScore rates CYYNF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Kilian Kelly
CEO
Kilian Kelly serves as the Chief Executive Officer of Cynata Therapeutics. His background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on strategic leadership and business development. He has held various senior management positions in both public and private companies, contributing to the advancement of innovative therapies. Kelly's expertise spans across clinical development, regulatory affairs, and commercialization strategies, making him well-suited to lead Cynata through its next phase of growth.
Track Record: Under Kilian Kelly's leadership, Cynata Therapeutics has focused on advancing its clinical programs, particularly the Phase III trial for CYP-004 in osteoarthritis. He has also overseen the strengthening of the company's strategic partnership with Fujifilm. Key milestones include the progression of CYP-001 through clinical trials and the development of CYP-006TK for diabetic wound care. His tenure has been marked by a commitment to innovation and strategic execution.
CYYNF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Cynata Therapeutics may not meet the minimum financial or reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited regulatory oversight and may not be required to file regular financial reports with the SEC. Investing in companies on the OTC Other tier carries higher risks compared to those listed on major exchanges like the NYSE or NASDAQ due to the potential for less transparency and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight and potential for less transparency.
- Lower trading volumes and wider bid-ask spreads.
- Increased price volatility.
- Potential for delisting or suspension of trading.
- Higher risk of fraud or manipulation.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any news or press releases about the company.
- Strategic partnership with Fujifilm.
- Clinical trials underway for multiple product candidates.
- Intellectual property protection for its Cymerus technology.
- Experienced management team.
- Scientific publications supporting its technology.
Cynata Therapeutics Limited Stock: Key Questions Answered
What does Cynata Therapeutics Limited do?
Cynata Therapeutics Limited is an Australian biotechnology company focused on developing and commercializing therapeutic stem cell technologies. Their core technology, Cymerus, allows for the mass production of mesenchymal stem cells (MSCs) for various therapeutic applications. The company's primary focus is on developing treatments for diseases with high unmet needs, such as graft-versus-host disease (GvHD) and osteoarthritis, using their proprietary MSCs. Cynata aims to provide scalable and cost-effective cell therapies through its innovative Cymerus platform and strategic partnerships.
What do analysts say about CYYNF stock?
As of 2026-03-16, formal analyst ratings for CYYNF may be limited due to its OTC listing and smaller market capitalization. However, the company's potential lies in its Cymerus technology and clinical trial progress. Investors should monitor key valuation metrics such as market capitalization ($0.05B), profit margin (9887.9%), and gross margin (253.3%) to assess the company's financial health. Growth considerations include the successful completion of clinical trials and regulatory approvals for its lead product candidates. The negative P/E ratio (-9.03) indicates that the company is not currently profitable.
What are the main risks for CYYNF?
Investing in Cynata Therapeutics carries inherent risks associated with biotechnology companies, including clinical trial failures, regulatory hurdles, and competition from established therapies. The company's reliance on its Cymerus technology and the success of its clinical programs makes it vulnerable to setbacks in research and development. Additionally, as an OTC-listed stock, CYYNF faces risks related to liquidity, transparency, and regulatory oversight. Financial constraints and the need for additional funding may also pose challenges to the company's long-term growth.
What are the key factors to evaluate for CYYNF?
Cynata Therapeutics Limited (CYYNF) currently holds an AI score of 54/100, indicating moderate score. Key strength: Proprietary Cymerus technology platform.. Primary risk to monitor: Potential: Clinical trial failures.. This is not financial advice.
How frequently does CYYNF data refresh on this page?
CYYNF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CYYNF's recent stock price performance?
Recent price movement in Cynata Therapeutics Limited (CYYNF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary Cymerus technology platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CYYNF overvalued or undervalued right now?
Determining whether Cynata Therapeutics Limited (CYYNF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CYYNF?
Before investing in Cynata Therapeutics Limited (CYYNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than major exchange data.